These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 16258763)

  • 1. Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer.
    Hu M; Chen P; Wang J; Chan C; Scollard DA; Reilly RM
    Eur J Nucl Med Mol Imaging; 2006 Mar; 33(3):301-10. PubMed ID: 16258763
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cellular penetration and nuclear importation properties of 111In-labeled and 123I-labeled HIV-1 tat peptide immunoconjugates in BT-474 human breast cancer cells.
    Cornelissen B; Hu M; McLarty K; Costantini D; Reilly RM
    Nucl Med Biol; 2007 Jan; 34(1):37-46. PubMed ID: 17210460
    [TBL] [Abstract][Full Text] [Related]  

  • 3. 123I-labeled HIV-1 tat peptide radioimmunoconjugates are imported into the nucleus of human breast cancer cells and functionally interact in vitro and in vivo with the cyclin-dependent kinase inhibitor, p21(WAF-1/Cip-1).
    Hu M; Chen P; Wang J; Scollard DA; Vallis KA; Reilly RM
    Eur J Nucl Med Mol Imaging; 2007 Mar; 34(3):368-77. PubMed ID: 17021818
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Properties of [(111)In]-labeled HIV-1 tat peptide radioimmunoconjugates in tumor-bearing mice following intravenous or intratumoral injection.
    Cornelissen B; McLarty K; Kersemans V; Scollard DA; Reilly RM
    Nucl Med Biol; 2008 Jan; 35(1):101-10. PubMed ID: 18158949
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Tat peptide immunoconjugates differentially sensitize breast cancer cells to selected antiproliferative agents that induce the cyclin-dependent kinase inhibitor p21WAF-1/CIP-1.
    Hu M; Wang J; Chen P; Reilly RM
    Bioconjug Chem; 2006; 17(5):1280-7. PubMed ID: 16984139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 111In-labeled immunoconjugates (ICs) bispecific for the epidermal growth factor receptor (EGFR) and cyclin-dependent kinase inhibitor, p27Kip1.
    Cornelissen B; Kersemans V; McLarty K; Tran L; Reilly RM
    Cancer Biother Radiopharm; 2009 Apr; 24(2):163-73. PubMed ID: 19409037
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vivo monitoring of intranuclear p27(kip1) protein expression in breast cancer cells during trastuzumab (Herceptin) therapy.
    Cornelissen B; Kersemans V; McLarty K; Tran L; Vallis KA; Reilly RM
    Nucl Med Biol; 2009 Oct; 36(7):811-9. PubMed ID: 19720293
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A comparison of non-biologically active truncated EGF (EGFt) and full-length hEGF for delivery of Auger electron-emitting 111In to EGFR-positive breast cancer cells and tumor xenografts in athymic mice.
    Panosa C; Fonge H; Ferrer-Batallé M; Menéndez JA; Massaguer A; De Llorens R; Reilly RM
    Nucl Med Biol; 2015 Dec; 42(12):931-8. PubMed ID: 26385534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of ErbB2-overexpressing breast cancer in vivo by a novel TAT-based ErbB2-targeting signal transducers and activators of transcription 3-blocking peptide.
    Tan M; Lan KH; Yao J; Lu CH; Sun M; Neal CL; Lu J; Yu D
    Cancer Res; 2006 Apr; 66(7):3764-72. PubMed ID: 16585203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. ¹¹¹In-Bn-DTPA-nimotuzumab with/without modification with nuclear translocation sequence (NLS) peptides: an Auger electron-emitting radioimmunotherapeutic agent for EGFR-positive and trastuzumab (Herceptin)-resistant breast cancer.
    Fasih A; Fonge H; Cai Z; Leyton JV; Tikhomirov I; Done SJ; Reilly RM
    Breast Cancer Res Treat; 2012 Aug; 135(1):189-200. PubMed ID: 22736376
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Human immunodeficiency virus-1 Tat protein up-regulates interleukin-6 and interleukin-8 expression in human breast cancer cells.
    Lee YW; Hirani AA; Kyprianou N; Toborek M
    Inflamm Res; 2005 Sep; 54(9):380-9. PubMed ID: 16273337
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
    J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Amplification of DNA damage by a γH2AX-targeted radiopharmaceutical.
    Cornelissen B; Darbar S; Kersemans V; Allen D; Falzone N; Barbeau J; Smart S; Vallis KA
    Nucl Med Biol; 2012 Nov; 39(8):1142-51. PubMed ID: 22819196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antibody spectrum against the viral transactivator protein in patients with human immunodeficiency virus type 1 infection and Kaposi's sarcoma.
    Demirhan I; Chandra A; Mueller F; Mueller H; Biberfeld P; Hasselmayer O; Chandra P
    J Hum Virol; 2000; 3(3):137-43. PubMed ID: 10881993
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A comparison of EGF and MAb 528 labeled with 111In for imaging human breast cancer.
    Reilly RM; Kiarash R; Sandhu J; Lee YW; Cameron RG; Hendler A; Vallis K; Gariépy J
    J Nucl Med; 2000 May; 41(5):903-11. PubMed ID: 10809207
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor effects and normal tissue toxicity of 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts.
    Chen P; Cameron R; Wang J; Vallis KA; Reilly RM
    J Nucl Med; 2003 Sep; 44(9):1469-78. PubMed ID: 12960194
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR.
    Reilly RM; Kiarash R; Cameron RG; Porlier N; Sandhu J; Hill RP; Vallis K; Hendler A; Gariépy J
    J Nucl Med; 2000 Mar; 41(3):429-38. PubMed ID: 10716315
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A synthetic HIV-1 Tat protein breaches the skin barrier and elicits Tat-neutralizing antibodies and cellular immunity.
    Partidos CD; Moreau E; Chaloin O; Tunis M; Briand JP; Desgranges C; Muller S
    Eur J Immunol; 2004 Dec; 34(12):3723-31. PubMed ID: 15549730
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cloning and molecular characterization of a human recombinant IgG Fab binding to the Tat protein of human immunodeficiency virus type 1 (HIV-1) derived from the repertoire of a seronegative patient.
    Mancini N; Perotti M; Carletti S; Canducci F; Sampaolo M; Clementi M; Burioni R
    Mol Immunol; 2006 Mar; 43(9):1363-9. PubMed ID: 16199090
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.